TIDMC4XD
RNS Number : 1455D
C4X Discovery Holdings PLC
05 October 2018
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR
INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES,
CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY
OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY
APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER TO SELL OR A
SOLICITATION TO BUY SECURITIES IN ANY JURISDICTION, INCLUDING THE
UNITED STATES, CANADA, AUSTRALIA, JAPAN AND THE REPUBLIC OF SOUTH
AFRICA. NEITHER THIS ANNOUNCEMENT NOR ANYTHING CONTAINED HEREIN
SHALL FORM THE BASIS OF, OR BE RELIED UPON IN CONNECTION WITH, ANY
OFFER OR COMMITMENT WHATSOEVER IN ANY JURISDICTION.
C4X Discovery Holdings plc
("C4XD" or the "Company")
Result of General Meeting and Open Offer
and
Issue of Equity
C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug
discovery company, today announces that at the General Meeting held
earlier today in connection with the Company's Placing and Open
Offer at a price of 90 pence per new Ordinary Share, details of
which were announced on 18 September 2018, all resolutions put to
shareholders were duly passed.
The Company also announces that it has received valid
acceptances in respect of 99,563 Open Offer Shares from Qualifying
Shareholders, including applications under the Excess Application
Facility. This represents approximately 9% of the 1,108,454 Open
Offer Shares offered. As a consequence and following the passing of
the resolutions at the General Meeting, and conditional on First
Admission and Second Admission, the Company has raised GBP10.1
million (before expenses) in aggregate through the Placing and Open
Offer.
Applications have been made for the 11,111,111 Placing Shares
and 99,563 Open Offer Shares to be admitted to trading on AIM. It
is expected that First Admission of the 3,379,997 Eligible Shares
will take place at 8.00 a.m. on 8 October 2018 and Second Admission
of the 7,731,114 General Placing Shares and 99,563 Open Offer
Shares will take place at 8.00 a.m. on 9 October 2018. The Placing
Shares and Open Offer Shares will rank pari passu with the existing
Ordinary Shares.
Following Second Admission, the Company's issued share capital
will consist of 57,765,761 Ordinary Shares. There are no Ordinary
Shares held in treasury. Therefore, in accordance with the FCA's
Disclosure and Transparency Rule 5.6.1, the Company confirms that
as at 9 October 2018, the total number of voting rights in the
Company will be 57,765,761. Following Second Admission, this figure
may be used by shareholders as the denominator for the calculations
by which they determine whether they are required to notify their
interest in, or a change to their interest in, C4XD under the
Disclosure Guidance and Transparency Rules.
The capitalised terms used in this announcement have the meaning
as defined in the announcement published by the Company at 1.53
p.m. on 18 September 2018 unless otherwise stated.
For further information, please contact:
C4X Discovery Holdings plc
Clive Dix, Chief Executive Officer 07801 865 803
Panmure Gordon (UK) Limited (NOMAD) 020 7886 2500
Freddy Crossley, Emma Earl (Corporate Finance)
James Stearns (Corporate Broking)
Consilium Strategic Communications
Mary-Jane Elliott, Matthew Neal, Chris Gardner 0203 709 5700
About C4X Discovery
C4X Discovery aims to become the world's most productive drug
discovery engine by exploiting cutting edge technologies to design
and create best-in-class small-molecule candidates targeting a
range of high value therapeutic areas. The company's goal is to
drive returns through early-stage revenue-generating deals with the
pharmaceutical industry.
C4X Discovery has a state-of-the-art suite of proprietary
technologies across the drug discovery process. The company's
innovative DNA-based target identification platform (Taxonomy3(R))
utilises human genetic datasets to identify novel patient-specific
targets leading to greater discovery productivity and increased
probability of clinical success. This is complemented by C4XD's
novel drug design platform which comprises two innovative chemistry
technologies, Conformetrix and Molplex, that combine 4D molecular
shape analyses (based on experimental data) with best-in-class
computational chemistry. This provides new and unprecedented
insight into the behaviour of drug molecules, enabling the
production of potent selective compounds faster and more cost
effectively than the industry standard.
C4X Discovery is advancing its in-house pipeline that is
primarily focused on the high value therapeutic areas of
inflammation, neurodegeneration and cancer (including
immuno-oncology) with a number of new drug candidates identified
and further progress made towards pre-clinical licensing
discussions. In selecting and executing new drug discovery
programmes, C4X Discovery focuses on high-value disease areas that
are the subject of significant licensing activity and will continue
to also maximise value from opportunistic areas such as addiction
and diabetes. The Company recently signed a licensing agreement
with Indivior for a pre-clinical addiction programme worth up to
$294 million.
The Company was founded as a spin-out from the University of
Manchester. It has a highly experienced management team and Board
who have delivered significant value creation within the healthcare
sector historically and have enabled C4XD to reach multiple value
inflexion points since IPO. For additional information please go
to: www.c4xdiscovery.com
IMPORTANT NOTICES
This Announcement has been issued by, and is the sole
responsibility of, the Company.
The content of this Announcement has not been approved by an
authorised person within the meaning of the Financial Services and
Markets Act 2000.
This Announcement is for information purposes only and is
directed only at: (a) persons in member states of the European
Economic Area who are qualified investors as defined in Article
(2)(1)(e) ("qualified investors") of Directive 2003/71/EC; and (b)
in the United Kingdom, qualified investors who are persons (1) who
have professional experience in matters relating to investments
falling within Article 19(1) (Investment Professionals) of the
Financial Services and Markets Act 2000 (Financial Promotion) Order
2005 (as amended) (the "Order"); (2) falling within Article
49(2)(a) to (d) (High net worth companies, unincorporated
associations, etc.) of the Order; or (3) other persons to whom it
may otherwise lawfully be communicated without being accompanied by
any further statements and/or warnings required by the Order and
not included in this Announcement (all such persons together being
referred to as "Relevant Persons").
This Announcement must not be acted on or relied on by persons
who are not Relevant Persons. Any investment or investment activity
to which this Announcement or the Placing relates is available only
to Relevant Persons and will be engaged in only with Relevant
Persons. As regards all persons other than Relevant Persons, the
details of the Placing set out in this Announcement are for
information purposes only.
Panmure Gordon (UK) Limited, which is authorised and regulated
in the United Kingdom by the Financial Conduct Authority (the
"FCA"), is acting as Nominated Adviser and broker to the Company
for the purposes of the AIM Rules for Companies and the AIM Rules
for Nominated Advisers in connection with the Placing and is not
acting for, and will not be responsible to, any person other than
the Company for providing the protections afforded to customers of
Panmure Gordon (UK) Limited or for advising any other person on any
transaction or arrangement referred to in this Announcement.
This Announcement may not be published, distributed, forwarded
or transmitted directly or indirectly, in whole or in part, in or
into the United States. These materials do not constitute an offer
to sell, or a solicitation of an offer to buy, securities in the
United States.
The New Ordinary Shares described in this Announcement have not
been, and will not be, registered under the U.S. Securities Act of
1933, as amended (the "US Securities Act"), or under the securities
laws of any state or other jurisdiction of the United States and
may not be offered, sold, resold, transferred or delivered,
directly or indirectly, within the United States except pursuant to
an exemption from, or in a transaction not subject to, the
registration requirements of the US Securities Act. The New
Ordinary Shares are being offered only outside of the United States
in reliance on Regulation S under the US Securities Act.
Furthermore, the New Ordinary Shares have not been and will not
be registered under the applicable laws of any of Canada,
Australia, Japan or the Republic of South Africa or of any other
jurisdiction where to do so would be unlawful and, consequently,
may not be offered or sold to any national, resident or citizen
thereof. The distribution of this Announcement in or into
jurisdictions other than the United Kingdom may be restricted by
law and therefore any person who is subject to the laws of any
jurisdiction other than the United Kingdom should inform themselves
about, and observe, such restrictions. Any failure to comply with
the applicable restrictions may constitute a violation of the
securities laws of any such jurisdiction.
FORWARD-LOOKING STATEMENTS
This Announcement contains (or may contain) certain
forward-looking statements with respect to certain of the Company's
plans and its current goals and expectations relating to its future
financial condition and performance and which involve a number of
risks and uncertainties. The Company cautions readers that no
forward-looking statement is a guarantee of future performance and
that actual results could differ materially from those contained in
the forward-looking statements. These forward-looking statements
can be identified by the fact that they do not relate only to
historical or current facts. Forward-looking statements sometimes
use words such as "aim", "anticipate", "target", "expect",
"estimate", "intend", "plan", "goal", "believe", "predict" or other
words of similar meaning. Examples of forward-looking statements
include, amongst others, statements regarding or which make
assumptions in respect of the planned use of the proceeds of the
Placing and Open Offer, the liquidity position of the Company and
its subsidiaries ("the Group"), the future performance of the
Group, future foreign exchange rates, interest rates and currency
controls, the future political and fiscal regimes in the overseas
markets in which the Group operates, the Group's future financial
position, plans and objectives for future operations and any other
statements that are not historical fact. By their nature,
forward-looking statements involve risk and uncertainty because
they relate to future events and circumstances, including, but not
limited to, economic and business conditions, the effects of
continued volatility in credit markets, market-related risks such
as changes in interest rates and foreign exchange rates, the
policies and actions of governmental and regulatory authorities,
changes in legislation, the further development of standards and
interpretations under International Financial Reporting Standards
("IFRS") applicable to past, current and future periods, evolving
practices with regard to the interpretation and application of
standards under IFRS, the outcome of pending and future litigation
or regulatory investigations, the success of future acquisitions
and other strategic transactions and the impact of competition. A
number of these factors are beyond the Company's control. As a
result, the Company's actual future results may differ materially
from the plans, goals, and expectations set forth in the Company's
forward-looking statements. Any forward-looking statements made in
this Announcement by or on behalf of the Company speak only as of
the date they are made. These forward-looking statements reflect
the Company's judgement at the date of this Announcement and are
not intended to give any assurance as to future results. Except as
required by the FCA, the London Stock Exchange, the AIM Rules or
applicable law, the Company expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
forward looking statements contained in this Announcement to
reflect any changes in the Company's expectations with regard
thereto or any changes in events, conditions or circumstances on
which any such statement is based.
--ENDS----
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ROMEAEESEENPFFF
(END) Dow Jones Newswires
October 05, 2018 06:11 ET (10:11 GMT)
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Jun 2024 to Jul 2024
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Jul 2023 to Jul 2024